Investors / Canada / Amplitude Ventures
Amplitude Ventures
Venture capital · Montreal, Canada · North America
Amplitude Ventures creates, builds and grows precision medicine companies developing treatments for patients. It also runs Pre-Amp, an internal engine that partners with academia and company builders to advance proof-of-concept data and drug discovery.
Invests inHealthcare & Biotech
In its own wordsprecision medicinebiotechmachine learningdrug discoverydiagnosticstherapeutics
Your fit with Amplitude Ventures
Four questions about your startup
See how your round matches what it backs, point by point.
Or find every investor that fitsAmplitude Ventures lists 3 checked portfolio companies on its own site and is named in 4 funding rounds, 2 of them as lead. Its most frequent entry is Series B, 100% of the companies with a known first round. Its largest theme is Healthcare & Biotech (100%). 67% of its companies are based in United States. It invests most often alongside Lumira Ventures, Agent Capital and Angelini Ventures.
Counts come from funding rounds that name Amplitude Ventures, complete from mid-2025: earlier rounds appear only when they were reported later. Round amounts and full round histories are on Fundup AI.
Entry stage
share of companies by the stage of its first roundAmplitude Ventures does not state its stages on its site, so only what it does is shown.
Show as a table
| Value | |
|---|---|
| Pre-seed | 0% |
| Seed | 0% |
| Series A | 0% |
| Series B | 100% |
| Growth | 0% |
Activity by year
rounds it joined, last 10 yearsShow as a table
| Total | Rounds it led | |
|---|---|---|
| '17 | 0 | 0 |
| '18 | 0 | 0 |
| '19 | 0 | 0 |
| '20 | 0 | 0 |
| '21 | 0 | 0 |
| '22 | 0 | 0 |
| '23 | 0 | 0 |
| '24 | 0 | 0 |
| '25 | 1 | 1 |
| '26 | 3 | 1 |
Invests most often with
firms sharing its portfolio companiesShow as a table
| Share | |
|---|---|
| Lumira Ventures | 2 |
| Agent Capital | 1 |
| Angelini Ventures | 1 |
| Asahi Kasei Ventures | 1 |
| CTI Life Sciences Fund | 1 |
| Dimension | 1 |
| Longwood Fund | 1 |
| Mission BioCapital | 1 |
Its portfolio companies
where they are based, and what their own sites showSite status
- Site answers3100%
- No longer answers00%
- Points to another company00%
- Parked or sold domain00%
A site that stops answering three checks in a row is counted as no longer answering; that is not proof of closure. A site that points to another company is often an acquisition.
Investment themes
share of its checked companiesThis firmAll checked companies
Show as a table
| This firm | All checked companies | |
|---|---|---|
| Healthcare & Biotech | 100% | 15% |
Co-investor network
who it backs companies with, and who they back togetherCompare Amplitude Ventures head to head
portfolio size, rounds, entry stages, themes and the companies both backThree or more firms at once: portfolio overlap.
Recent portfolio activity
when companies last raised with Amplitude Ventures| Date | Company | Stage |
|---|---|---|
| 3 Nov 2026 | Series B | |
| 19 Mar 2026 | Round | |
| 7 Jan 2026 | Series B Led | |
| 4 Sept 2025 | Round Led |
Round details for Amplitude Ventures
Amounts, full round histories and every co-investor in Amplitude Ventures' rounds are on Fundup AI. VCinfo covers investors and their portfolios.
Portfolio
3 companies checked against their own sites| Company | What it does | Themes | First round with it | Evidence |
|---|---|---|---|---|
| Congruence Therapeutics is a clinical-stage biotechnology company that discovers and develops small molecule correctors and allosteric modulators to ameliorate disease conditions at the molecular level. | Healthcare & Biotech | Sept 2025Round · 2 rounds | Funding round | |
| Mediar Therapeutics is developing treatments for fibrotic diseases by targeting the myofibroblast cell | Healthcare & Biotech | Jan 2026Series B | Funding round | |
| Thryv Therapeutics is a clinical-stage biotechnology company advancing a portfolio of potent, selective inhibitors of serum and glucocorticoid-regulated kinase 1 (SGK1) as precision medicines for inherited channelopathies, cardiometabolic diseases and cardiomyopathies. | Healthcare & Biotech | Nov 2026Series B | Funding round |
About this data
site last read 5 Nov 2026- Site
- amplitudevc.com
- Last read
- 5 Nov 2026
- Watching since
- 6 Nov 2026
- Rounds since
- 4 Sept 2025
- Companies checked
- 3
Rates come from what VCinfo has observed since observation_start. Firms tend to remove companies that closed, so early rates understate reality. A company leaving a portfolio page does not mean it closed or exited. An unreachable site means our checks failed, nothing more.
Get Amplitude Ventures' profile as data
Pull Amplitude Ventures' portfolio, co-investors and changes through one API key or MCP, open every portfolio row, compare it with other firms, and get an email when it adds a company or files a fund.
Work email, sign-in link by email. Already have an account? Log in- Ask AI5 plain-English investor searches a day
- Full listsEvery portfolio row and two-firm overlap
- API and MCP100 REST or MCP calls a month, one key
- AlertsFollow 5 investors for portfolio and fund changes
$ curl -H "X-API-Key: YOUR_KEY" \
https://api.vcinfo.io/v1/firms/amplitudevc.com
# also
GET /v1/firms/amplitudevc.com/portfolio
GET /v1/firms/amplitudevc.com/coinvestors
GET /v1/firms/amplitudevc.com/news